[Research Report] The transcranial magnetic stimulator (TMS) market is projected to reach US$ 2,029.71 million by 2028 from US$ 1,122.22 million in 2021; it is expected to register a CAGR of 8.8% from 2021 to 2028.

Neurological disorders affect the brain and nerves of the human body and cause epilepsy and seizures, Parkinson's disease, dementia, autism, Alzheimer's disease, brain tumors, and cerebral palsy, among others. The prevalence of neurological disorders is increasing across the world. According to the Global Burden of Disease Study (GBD) 2017, Alzheimer’s disease and other dementias [2.55 million Disability Adjusted Life Years (DALYs)], stroke [about 3.58 million DALYs], and migraine (about 2.40 million DALYs) were the three most burdensome neurological diseases in the US in terms of a total number of disability-adjusted life.

Further, the Alzheimer's Association estimates that over 6 million Americans have Alzheimer's disease, and the number is projected to reach nearly 13 million by 2050. Transcranial Magnetic Stimulator (TMS) is widely used for the diagnosis and treatment of neurological disorders. For instance, according to BrainsWay Ltd., in April 2021, 100,000 patients across the world were treated with its Deep TMS. Thus, the growing prevalence of neurological disorders drives the growth of the transcranial magnetic stimulator (TMS) market globally. Moreover, depression is one of the mental disorders observed commonly among people worldwide. As per the data published by WHO in January 2020, more than 264 million people of all ages suffer from depression across the world.

Customize Research To Suit Your Requirement

We can optimize and tailor the analysis and scope which is unmet through our standard offerings. This flexibility will help you gain the exact information needed for your business planning and decision making.

Get 10% FREE CUSTOMIZATION

Transcranial Magnetic Stimulator (TMS) Market: Strategic Insights

Transcranial Magnetic Stimulator (TMS) Market

• 
  CAGR (2021 - 2028)

  8.8%
• Market Size 2021
  US$ 1.12 Billion
• Market Size 2028
  US$ 2.03 Billion

Market Dynamics

GROWTH DRIVERS

• XXXXXXX
• XXXXXXX
• XXXXXXX

FUTURE TRENDS

• XXXXXXX
• XXXXXXX
• XXXXXXX

OPPORTUNITIES

• XXXXXXX
• XXXXXXX
• XXXXXXX

Key Players

• BrainsWay Ltd
• Nexstim
• Magstim
• Neuronetics
• TMS Neuro Solutions
• MagVenture, Inc.
• eNeura Inc.
• Neurosoft
• MAG & More GmbH.

Regional Overview

• North America
• Europe
• Asia-Pacific
• South and Central America
• Middle East and Africa

Market Segmentation

Type

• Single or Paired Pulse TMS
• Repetitive TMS

Age Group

• Adults
• Children

Application

• Research
• Diagnostic
• Therapeutic

Geography

• North America
• Europe
• Asia Pacific
• Middle East and Africa
• South and Central America

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Market Insights

Transcranial magnetic stimulation (TMS) is a noninvasive procedure that helps in treating neurological disorders. In addition, growing technological developments in TMS have increased its applications. Companies operating in the transcranial magnetic stimulator (TMS) market are adopting various strategies such as receiving Food and Drug Administration (FDA) approvals for their innovative products, business partnerships, and raising funds for product development, which propel the market growth.

The following are a few examples of developments:

• In March 2021, MagVenture introduced the MagVenture Flow Arm—a patent-pending, clinical positioning system—designed to optimize the delivery of MagVenture's FDA-cleared protocols for noninvasive brain stimulation technology for the treatment of major depressive disorder and as an adjunct therapy for obsessive compulsive disorder (OCD).
• In August 2020, MagVenture TMS Therapy received FDA clearance for the adjunct treatment of OCD. It is the second indication in the US for the Danish medical device company MagVenture.
• In February 2019, eNeura, Inc., a privately held medical technology company, announced a new 510(k) clearance from FDA. With the clearance, the company claimed that the sTMS is the only migraine product in the US for the treatment of acute and prophylactic migraine headaches in adults and children (12 years and above).

Thus, the active involvement of the global players in the development of transcranial magnetic stimulation and related technologies is expected to support the market growth.

Type-Based Insights

Based on type, the transcranial magnetic stimulator (TMS) market is segmented into single or paired pulse TMS and repetitive TMS (rTMS). In 2021, the single or paired pulse TMS segment held a larger share of the market. However, the repetitive TMS (rTMS) segment is expected to witness a higher CAGR during 2021–2028.

Application-Based Insights

Based on application, the market is segmented into research, diagnostic, and therapeutic. In 2021, the diagnostic segment held the largest share of the market and is expected to grow at the highest CAGR during the coming years.

Companies operating in the transcranial magnetic stimulator (TMS) market emphasize on adopting the strategy of product innovations to meet the evolving customer demands across the world, which also permits them to maintain their brand name in the global market.

Transcranial Magnetic Stimulator Market Report Scope

Download Free Sample

   Buy Now   

• Sample PDF showcases the content structure and the nature of the information with qualitative and quantitative analysis.

Transcranial Magnetic Stimulator (TMS) Market – Segmentation

By Type

• Single or Paired Pulse TMS
• Repetitive TMS (rTMS)

By Age Group

• Adults
• Children

By Application

• Research
• Diagnostic
• Therapeutic

By Geography

• North America
  • US
  • Canada
  • Mexico
• Europe
  • France
  • Germany
  • Italy
  • UK
  • Spain
  • Rest of Europe
• Asia Pacific (APAC)
  • China
  • India
  • South Korea
  • Japan
  • Australia
  • Rest of APAC
• Middle East and Africa (MEA)
  • South Africa
  • Saudi Arabia
  • UAE
  • Rest of MEA
• South and Central America (SCAM)
  • Brazil
  • Argentina
  • Rest of SCAM

Company Profiles

• BrainsWay Ltd
• Nexstim, Magstim
• Neuronetics
• TMS Neuro Solutions
• MagVenture, Inc.
• eNeura Inc.
• Neurosoft
• MAG & More GmbH